BridgeMD
New treatment option for Chronic Pain
Official title Conditioned Open-label Placebos to Facilitate Opioid Reduction in Patients With Subacute or Chronic Pain Pain: a Randomized Controlled Trial
ClinicalTrials.gov ID: NCT06350786
What this study is testing
- What it's testing
- This study aims to evaluate whether the reduction of the daily morphine equivalent dose (MED) in patients with subacute and chronic pain can be decreased with an open-label placebo (OLP) intervention in comparison to an electronic monitoring (EM) control group. The participants will receive the intervention (OPL or EM) over the duration of six weeks.
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Signed Informed Consent
- ≥ 18 years of age
- German speaking
- Pain lasting ≥ 4 weeks, including subacute pain (4-12 weeks) and chronic pain (\>12 weeks)
- Opioid medication for pain management for ≥ 4 weeks
You likely can't join if
- Having psychotic symptoms
- Suicidality
- Cognitive impairment to everyday life
- Planned surgery within the next two months that is expected to affect opioid intake
- Known illegal drug or harmful alcohol consumption
- Intolerance of the ingredients of the placebo pill (e.g., lactose, sucrose, corn-starch)
See the full eligibility criteria
- Signed Informed Consent
- ≥ 18 years of age
- German speaking
- Pain lasting ≥ 4 weeks, including subacute pain (4-12 weeks) and chronic pain (\>12 weeks)
- Opioid medication for pain management for ≥ 4 weeks
- Oral intake of opioid medication
- Motivation for opioid reduction
- Participants have a primary treating physician who performs the reduction of the opioid medication
- Having access to a computer or tablet with an email-account
- Having psychotic symptoms
- Suicidality
- Cognitive impairment to everyday life
- Planned surgery within the next two months that is expected to affect opioid intake
- Known illegal drug or harmful alcohol consumption
- Intolerance of the ingredients of the placebo pill (e.g., lactose, sucrose, corn-starch)
- Serious health problems that make study participation impossible
- Simultaneous participation in other studies with investigational drugs or pain specific interventions
The study team makes the final eligibility decision.
Where it's taking place
- Zurich, Canton of Zurich, Switzerland
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Zurich, Canton of Zurich, Switzerland. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.